| dc.contributor.author |
Yigenoglu, TN |
|
| dc.contributor.author |
Basci, S |
|
| dc.contributor.author |
Sahin, D |
|
| dc.contributor.author |
Ulas, T |
|
| dc.contributor.author |
Dal, MS |
|
| dc.contributor.author |
Korkmaz, S |
|
| dc.contributor.author |
Hacibekiroglu, T |
|
| dc.contributor.author |
Namdaroglu, S |
|
| dc.contributor.author |
Erkurt, MA |
|
| dc.contributor.author |
Turgut, B |
|
| dc.contributor.author |
Altuntas, F |
|
| dc.date.accessioned |
2022-10-05T13:20:11Z |
|
| dc.date.available |
2022-10-05T13:20:11Z |
|
| dc.date.issued |
2021 |
|
| dc.identifier.uri |
http://hdl.handle.net/11616/62716 |
|
| dc.description.abstract |
SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARSCoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment. |
|
| dc.description.abstract |
C1 [Yigenoglu, Tugce Nur; Basci, Semih; Sahin, Derya; Dal, Mehmet Sinan; Altuntas, Fevzi] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol & Bone Marrow Transplantat Ctr, Ankara, Turkey. |
|
| dc.description.abstract |
[Ulas, Turgay] Near East Univ, Sch Med, Dept Hematol, Dept Internal Med, Nicosia, Cyprus. |
|
| dc.description.abstract |
[Korkmaz, Serdal] Univ Hlth Sci, Kayseri Training & Res Hosp, Dept Hematol, Kayseri, Turkey. |
|
| dc.description.abstract |
[Korkmaz, Serdal] Univ Hlth Sci, Kayseri Training & Res Hosp, Bone Marrow Transplantat Ctr, Kayseri, Turkey. |
|
| dc.description.abstract |
[Hacibekiroglu, Tuba] Sakarya Univ, Sch Med, Div Hematol, Dept Internal Med, Sakarya, Turkey. |
|
| dc.description.abstract |
[Namdaroglu, Sinem] Univ Hlth Sci, Bozyaka Training & Res Hosp, Dept Hematol & Bone Marrow Transplantat Ctr, Izmir, Turkey. |
|
| dc.description.abstract |
[Erkurt, Mehmet Ali] Inonu Univ, Sch Med, Div Hematol, Dept Internal Med, Malatya, Turkey. |
|
| dc.description.abstract |
[Erkurt, Mehmet Ali] Inonu Univ, Sch Med, Bone Marrow Transplantat Ctr, Dept Internal Med, Malatya, Turkey. |
|
| dc.description.abstract |
[Turgut, Burhan] Namik Kemal Univ, Sch Med, Div Hematol, Dept Internal Med, Tekirdag, Turkey. |
|
| dc.description.abstract |
[Turgut, Burhan] Namik Kemal Univ, Sch Med, Hematol & Bone Marrow Transplantat Ctr, Dept Internal Med, Tekirdag, Turkey. |
|
| dc.description.abstract |
[Altuntas, Fevzi] Ankara Yildirim Beyazit Univ, Sch Med, Div Hematol, Dept Internal Med, Ankara, Turkey. |
|
| dc.source |
TRANSFUSION AND APHERESIS SCIENCE |
|
| dc.title |
Mesenchymal stem cell transfusion: Possible beneficial effects in |
|